Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Reminertant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 known ✓ | P30989 | 9/20 | 1.00 |
| ▸ | NTSR2 | O95665 | 2/20 | 1.00 |
| ▸ | FPR3 | P25089 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | SORT1 | Q99523 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Reminertant SCHEMBL1650932 | 1.00 | NTSR1 (1.00) | NTSR1NTSR2FPR3GPR183SORT1 | |
| SCHEMBL19026903 | 0.93 | NTSR1 (0.87) | NTSR1NTSR2FPR3GPR183SORT1 | |
| SCHEMBL7556717 | 0.90 | NTSR1 (0.81) | NTSR1NTSR2FPR3GPR183SORT1 | |
| SCHEMBL8590399 | 0.89 | NTSR1 (0.80) | NTSR1NTSR2FPR3GPR183SORT1 | |
| SCHEMBL9078221 | 0.85 | NTSR1 (0.75) | NTSR1NTSR2FPR3GPR183SORT1 | |
| SCHEMBL17114634 | 0.85 | NTSR1 (0.75) | NTSR1NTSR2FPR3GPR183SORT1 | |
| SCHEMBL17114585 | 0.85 | NTSR1 (0.75) | NTSR1NTSR2FPR3GPR183SORT1 | |
| SCHEMBL17114586 | 0.85 | NTSR1 (0.74) | NTSR1NTSR2FPR3GPR183SORT1 | |
| SCHEMBL17114581 | 0.85 | NTSR1 (0.74) | NTSR1NTSR2FPR3GPR183SORT1 | |
| SCHEMBL8591222 | 0.84 | NTSR1 (0.72) | NTSR1NTSR2FPR3GPR183SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119074732-A | Application of NTSR1 inhibitor in treating chronic nasosinusitis | 南京市中西医结合医院 | 2024-12-06 | — | — | CN | claimed |
| US-20260146036-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2026-05-28 | — | — | US | disclosed |
| US-20260139031-A1 | FUSION PROTEIN | LEVICEPT LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4377309-B1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC (JP) | 2026-05-20 | — | — | EP | disclosed |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SEVENLESS THERAPEUTICS LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| US-12605447-B2 | Stable formulations for radionuclide complexes | ITM SOLUCIN GMBH (DE) | 2026-04-21 | — | — | US | disclosed |
| EP-4719596-A1 | FUSION PROTEIN | Levicept Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720104-A1 | LOW AFFINITY P75 NEUROTROPHIC RECEPTOR EXTRACELLULAR DOMAIN FUSED TO A FC MOIETY AS NGF ANTAGONIST THERAPY OF PAIN | Levicept Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4712957-A2 | ISOANDROGRAPHOLIDE ANALOGS AND METHOD FOR TREATMENT USING THE SAME | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712967-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20220110923-A1 | ESTERS AND CARBAMATES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-04-14 | — | — | US | disclosed |
| WO-2022071484-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2022-04-07 | — | — | WO | disclosed |
| EP-3976594-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | The Schepens Eye Research Institute, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114206849-A | Therapeutic methods for treating non-infectious ocular immunoinflammatory disorders | 斯格本斯眼科研究所有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3965751-A1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM Isotope Technologies Munich SE (DE) | 2022-03-16 | — | — | EP | disclosed |
| CN-114126654-A | Para-aminohippuric acid (PAH) as a kidney protective substance | 同位素技术慕尼黑有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605447-B2 | Stable formulations for radionuclide complexes | EPOR, CD47, PRCP | NTSR1 71/4885NTSR2 158/4885FPR3 1144/4885 |
| US-20260146036-A1 | CRYSTALLINE FORMS | PRKCD, CCT8, CRYZ | NTSR1 4572/4885NTSR2 4106/4885FPR3 4422/4885 |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SOS1, OPRL1, SOS2 | NTSR1 122/4885NTSR2 148/4885FPR3 715/4885 |
| US-20220110923-A1 | ESTERS AND CARBAMATES AS MODULATORS OF SODIUM CHANNELS | SCN10A, CACNA1A, SCN3A | NTSR1 1608/4885NTSR2 1121/4885FPR3 3631/4885 |
| US-20260139031-A1 | FUSION PROTEIN | NTRK2, BDNF, NGFR | NTSR1 37/4885NTSR2 39/4885FPR3 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.